Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Lansoprazole is an antituberculous prodrug targeting cytochrome bc1.

Rybniker J, Vocat A, Sala C, Busso P, Pojer F, Benjak A, Cole ST.

Nat Commun. 2015 Jul 9;6:7659. doi: 10.1038/ncomms8659.

2.

Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of Mycobacterium tuberculosis.

Foo CS, Lupien A, Kienle M, Vocat A, Benjak A, Sommer R, Lamprecht DA, Steyn AJC, Pethe K, Piton J, Altmann KH, Cole ST.

MBio. 2018 Oct 9;9(5). pii: e01276-18. doi: 10.1128/mBio.01276-18.

3.

Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.

Andersson T.

Clin Pharmacokinet. 1996 Jul;31(1):9-28. Review. Erratum in: Clin Pharmacokinet 1996 Oct;31(4):274.

PMID:
8827397
4.

The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.

Ogilvie BW, Yerino P, Kazmi F, Buckley DB, Rostami-Hodjegan A, Paris BL, Toren P, Parkinson A.

Drug Metab Dispos. 2011 Nov;39(11):2020-33. doi: 10.1124/dmd.111.041293. Epub 2011 Jul 27.

PMID:
21795468
5.

Lansoprazole use and tuberculosis incidence in the United Kingdom Clinical Practice Research Datalink: A population based cohort.

Yates TA, Tomlinson LA, Bhaskaran K, Langan S, Thomas S, Smeeth L, Douglas IJ.

PLoS Med. 2017 Nov 21;14(11):e1002457. doi: 10.1371/journal.pmed.1002457. eCollection 2017 Nov.

6.

Stereoselective disposition of proton pump inhibitors.

Andersson T, Weidolf L.

Clin Drug Investig. 2008;28(5):263-79. Review.

PMID:
18407713
7.

Lansoprazole: a proton pump inhibitor.

Garnett WR.

Ann Pharmacother. 1996 Dec;30(12):1425-36. Review.

PMID:
8968456
8.

[Prospects for development of new antituberculous drugs].

Tomioka H.

Kekkaku. 2002 Aug;77(8):573-84. Japanese.

PMID:
12235850
9.

Omeprazole, lansoprazole and pantoprazole had no effect on blood pressure and electrocardiogram of anesthetized rat.

Yenişehirli A, Naseri E.

Pharmacol Res. 2008 Jul;58(1):65-71. doi: 10.1016/j.phrs.2008.06.012. Epub 2008 Jul 5.

PMID:
18647653
10.

Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.

Liu Y, Zhou S, Deng Q, Li X, Meng J, Guan Y, Li C, Xiao C.

Tuberculosis (Edinb). 2016 Mar;97:38-46. doi: 10.1016/j.tube.2015.12.003. Epub 2016 Jan 6.

PMID:
26980494
11.

Activity of 2-(quinolin-4-yloxy)acetamides in Mycobacterium tuberculosis clinical isolates and identification of their molecular target by whole-genome sequencing.

Subtil FT, Villela AD, Abbadi BL, Rodrigues-Junior VS, Bizarro CV, Timmers LFSM, de Souza ON, Pissinate K, Machado P, López-Gavín A, Tudó G, González-Martín J, Basso LA, Santos DS.

Int J Antimicrob Agents. 2018 Mar;51(3):378-384. doi: 10.1016/j.ijantimicag.2017.08.023. Epub 2017 Aug 23.

12.

Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.

Çelebi A, Aydın D, Kocaman O, Konduk BT, Şentürk Ö, Hülagü S.

Turk J Gastroenterol. 2016 Sep;27(5):408-414. doi: 10.5152/tjg.2016.15514.

13.

Pyrrolo[3,4-c]pyridine-1,3(2H)-diones: A Novel Antimycobacterial Class Targeting Mycobacterial Respiration.

van der Westhuyzen R, Winks S, Wilson CR, Boyle GA, Gessner RK, Soares de Melo C, Taylor D, de Kock C, Njoroge M, Brunschwig C, Lawrence N, Rao SP, Sirgel F, van Helden P, Seldon R, Moosa A, Warner DF, Arista L, Manjunatha UH, Smith PW, Street LJ, Chibale K.

J Med Chem. 2015 Dec 10;58(23):9371-81. doi: 10.1021/acs.jmedchem.5b01542. Epub 2015 Nov 20.

PMID:
26551248
14.

Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.

Zvyaga T, Chang SY, Chen C, Yang Z, Vuppugalla R, Hurley J, Thorndike D, Wagner A, Chimalakonda A, Rodrigues AD.

Drug Metab Dispos. 2012 Sep;40(9):1698-711. doi: 10.1124/dmd.112.045575. Epub 2012 May 30.

PMID:
22648560
16.

Proton pump inhibitor lansoprazole is a nuclear liver X receptor agonist.

Cronican AA, Fitz NF, Pham T, Fogg A, Kifer B, Koldamova R, Lefterov I.

Biochem Pharmacol. 2010 May 1;79(9):1310-6. doi: 10.1016/j.bcp.2009.12.018. Epub 2010 Jan 8.

17.

Proton pump inhibitors omeprazole, lansoprazole and pantoprazole induce relaxation in the rat lower oesophageal sphincter.

Yurtsever AS, Pektas M, Ozkur M, Un I, Erenmemisoglu A, Buyukafsar K.

J Pharm Pharmacol. 2011 Oct;63(10):1295-300. doi: 10.1111/j.2042-7158.2011.01333.x. Epub 2011 Jul 19.

PMID:
21899545
18.

Inhibition of lysosomal enzyme activities by proton pump inhibitors.

Liu W, Baker SS, Trinidad J, Burlingame AL, Baker RD, Forte JG, Virtuoso LP, Egilmez NK, Zhu L.

J Gastroenterol. 2013 Dec;48(12):1343-52. doi: 10.1007/s00535-013-0774-5. Epub 2013 Mar 12.

PMID:
23478938
19.

Esters of Pyrazinoic Acid Are Active against Pyrazinamide-Resistant Strains of Mycobacterium tuberculosis and Other Naturally Resistant Mycobacteria In Vitro and Ex Vivo within Macrophages.

Pires D, Valente E, Simões MF, Carmo N, Testa B, Constantino L, Anes E.

Antimicrob Agents Chemother. 2015 Dec;59(12):7693-9. doi: 10.1128/AAC.00936-15. Epub 2015 Oct 5.

20.

Enantioselective disposition of omeprazole, pantoprazole, and lansoprazole in a same Brazilian subjects group.

Cassiano NM, Oliveira RV, Bernasconi GC, Cass QB.

Chirality. 2012 Apr;24(4):289-93. doi: 10.1002/chir.21995. Epub 2012 Feb 17.

PMID:
22344845

Supplemental Content

Support Center